{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:37:24Z","timestamp":1790617044579,"version":"4.1.0"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100157"],"award-info":[{"award-number":["82100157"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06117-9","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:26:57Z","timestamp":1732768017000},"page":"4883-4899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies"],"prefix":"10.1007","volume":"103","author":[{"given":"Chenyu","family":"Zha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"10393","key":"6117_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD Dinardo","year":"2023","unstructured":"Dinardo CD, Erba HP, Freeman SD, Wei AH (2023) Acute myeloid leukaemia. Lancet 401(10393):2073\u20132086. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3","journal-title":"Lancet"},{"issue":"3","key":"6117_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"6117_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005","journal-title":"Blood Rev"},{"issue":"5","key":"6117_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of Cancer: the Next Generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"18","key":"6117_CR5","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1158\/1078-0432.CCR-21-1804","volume":"28","author":"MM Gubin","year":"2022","unstructured":"Gubin MM, Vesely MD (2022) Cancer Immunoediting in the era of Immuno-Oncology. Clin Cancer Res 28(18):3917\u20133928. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1804","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6117_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16(3):151\u2013167. https:\/\/doi.org\/10.1038\/s41571-018-0142-8","journal-title":"Nat Rev Clin Oncol"},{"key":"6117_CR7","doi-asserted-by":"publisher","unstructured":"Sauerer T, Velazquez GF, Schmid C (2023) Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. Mol Cancer 22(1). https:\/\/doi.org\/10.1186\/s12943-023-01889-6","DOI":"10.1186\/s12943-023-01889-6"},{"issue":"5","key":"6117_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.20.00475","volume":"39","author":"S Khaldoyanidi","year":"2021","unstructured":"Khaldoyanidi S, Nagorsen D, Stein A, Ossenkoppele G, Subklewe M (2021) Immune Biology of Acute myeloid leukemia: implications for Immunotherapy. J Clin Oncol 39(5):419. https:\/\/doi.org\/10.1200\/JCO.20.00475","journal-title":"J Clin Oncol"},{"issue":"1","key":"6117_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS (2020) Top 10 challenges in Cancer Immunotherapy. Immunity 52(1):17\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.011","journal-title":"Immunity"},{"key":"6117_CR10","doi-asserted-by":"publisher","unstructured":"Gu R, Yang X, Wei H (2018) Molecular landscape and targeted therapy of acute myeloid leukemia. Biomark Res 6. https:\/\/doi.org\/10.1186\/s40364-018-0146-7","DOI":"10.1186\/s40364-018-0146-7"},{"key":"6117_CR11","doi-asserted-by":"publisher","unstructured":"Epperly R, Gottschalk S, Velasquez MP (2020) A bump in the Road: how the hostile AML Microenvironment affects CAR T cell therapy. Front Oncol 10. https:\/\/doi.org\/10.3389\/fonc.2020.00262","DOI":"10.3389\/fonc.2020.00262"},{"key":"6117_CR12","doi-asserted-by":"publisher","unstructured":"Peng M, Ren J, Jing Y, Jiang X, Xiao Q, Huang J, Tao Y, Lei L, Wang X, Yang Z et al (2021) Tumour-derived small extracellular vesicles suppress CD8\u2009+\u2009T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia. J Extracell Vesicles 10(13). https:\/\/doi.org\/10.1002\/jev2.12168","DOI":"10.1002\/jev2.12168"},{"key":"6117_CR13","doi-asserted-by":"publisher","unstructured":"Guo R, Lu M, Cao F, Wu G, Gao F, Pang H, Li Y, Zhang Y, Xing H, Liang C et al (2021) Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res 9(1). https:\/\/doi.org\/10.1186\/s40364-021-00265-0","DOI":"10.1186\/s40364-021-00265-0"},{"issue":"25","key":"6117_CR14","doi-asserted-by":"publisher","first-page":"14331","DOI":"10.1073\/pnas.1916206117","volume":"117","author":"AJ Lamble","year":"2020","unstructured":"Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, Wang W, Long N, Saultz JN, Mori M et al (2020) Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proc Natl Acad Sci U S A 117(25):14331\u201314341. https:\/\/doi.org\/10.1073\/pnas.1916206117","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"6117_CR15","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","volume":"114","author":"R Le Dieu","year":"2009","unstructured":"Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, Lee AM, Lister TA, Gribben JG (2009) Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 114(18):3909\u20133916. https:\/\/doi.org\/10.1182\/blood-2009-02-206946","journal-title":"Blood"},{"issue":"6","key":"6117_CR16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.25791","volume":"129","author":"S Zhang","year":"2011","unstructured":"Zhang S, Han Y, Wu J, Yu K, Bi L, Zhuang Y, Xu X (2011) Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 129(6):1373\u20131381. https:\/\/doi.org\/10.1002\/ijc.25791","journal-title":"Int J Cancer"},{"key":"6117_CR17","doi-asserted-by":"publisher","unstructured":"Wang H, Tao Q, Wang Z, Zhang Q, Xiao H, Zhou M, Dong Y, Zhai Z (2020) Circulating Monocytic Myeloid-Derived Suppressor Cells Are Elevated and Associated with Poor Prognosis in Acute Myeloid Leukemia. J Immunol Res 2020. https:\/\/doi.org\/10.1155\/2020\/7363084","DOI":"10.1155\/2020\/7363084"},{"key":"6117_CR18","doi-asserted-by":"publisher","unstructured":"Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, Avelar PHDC, Tsoka S, Bullinger L, Seubert E, Smit DJ et al (2022) TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis. J Immunother Cancer 10(12). https:\/\/doi.org\/10.1136\/jitc-2022-004794","DOI":"10.1136\/jitc-2022-004794"},{"key":"6117_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00870-6","author":"S Kumagai","year":"2024","unstructured":"Kumagai S, Itahashi K, Nishikawa H (2024) Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-024-00870-6","journal-title":"Nat Rev Clin Oncol"},{"issue":"24","key":"6117_CR20","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.2020006158","volume":"136","author":"DA Sallman","year":"2020","unstructured":"Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou H, Eksioglu EA, Sullivan A et al (2020) TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood 136(24):2812\u20132823. https:\/\/doi.org\/10.1182\/blood.2020006158","journal-title":"Blood"},{"key":"6117_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01080-3","author":"J Yang","year":"2023","unstructured":"Yang J, Bae H (2023) Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment. Exp Mol Med. https:\/\/doi.org\/10.1038\/s12276-023-01080-3","journal-title":"Exp Mol Med"},{"issue":"10","key":"6117_CR22","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","volume":"15","author":"MJ Szczepanski","year":"2009","unstructured":"Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M (2009) Increased Frequency and Suppression by Regulatory T Cells in patients with Acute Myelogenous Leukemia. Clin Cancer Res 15(10):3325\u20133332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6117_CR23","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.12774","volume":"165","author":"N Dulphy","year":"2014","unstructured":"Dulphy N, Henry G, Hemon P, Khaznadar Z, Dombret H, Boissel N, Bensussan A, Toubert A (2014) Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. Br J Haematol 165(5):722\u2013725. https:\/\/doi.org\/10.1111\/bjh.12774","journal-title":"Br J Haematol"},{"key":"6117_CR24","doi-asserted-by":"publisher","unstructured":"Boutilier AJ, Elsawa SF (2021) Macrophage polarization States in the Tumor Microenvironment. Int J Mol Sci 22(13). https:\/\/doi.org\/10.3390\/ijms22136995","DOI":"10.3390\/ijms22136995"},{"issue":"6","key":"6117_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.it.2010.04.001","volume":"31","author":"S Jaiswal","year":"2010","unstructured":"Jaiswal S, Chao MP, Majeti R, Weissman IL (2010) Macrophages as mediators of tumor immunosurveillance. Trends Immunol 31(6):212\u2013219. https:\/\/doi.org\/10.1016\/j.it.2010.04.001","journal-title":"Trends Immunol"},{"issue":"6","key":"6117_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19(6):369\u2013382. https:\/\/doi.org\/10.1038\/s41577-019-0127-6","journal-title":"Nat Rev Immunol"},{"key":"6117_CR27","doi-asserted-by":"publisher","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, Lin L (2024) Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol 8(1). https:\/\/doi.org\/10.1038\/s41698-024-00522-z","DOI":"10.1038\/s41698-024-00522-z"},{"issue":"5","key":"6117_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","volume":"122","author":"F Mussai","year":"2013","unstructured":"Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, Qureshi A, Dazzi F, Vyas P, Cerundolo V (2013) Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 122(5):749\u2013758. https:\/\/doi.org\/10.1182\/blood-2013-01-480129","journal-title":"Blood"},{"issue":"10","key":"6117_CR29","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3324\/haematol.2016.143180","volume":"101","author":"YS Al-Matary","year":"2016","unstructured":"Al-Matary YS, Botezatu L, Opalka B, H\u00f6nes JM, Lams RF, Thivakaran A, Sch\u00fctte J, K\u00f6ster R, Lennartz K, Schroeder T et al (2016) Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a growth factor independence 1 dependent manner. Haematologica 101(10):1216\u20131227. https:\/\/doi.org\/10.3324\/haematol.2016.143180","journal-title":"Haematologica"},{"issue":"6","key":"6117_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00281-018-0698-5","volume":"40","author":"TA Werfel","year":"2018","unstructured":"Werfel TA, Cook RS (2018) Efferocytosis in the tumor microenvironment. Semin Immunopathol 40(6):545\u2013554. https:\/\/doi.org\/10.1007\/s00281-018-0698-5","journal-title":"Semin Immunopathol"},{"key":"6117_CR31","doi-asserted-by":"publisher","unstructured":"Cruz JC, Allison KC, Page LS, Jenkins AJ, Wang XD, Earp HS, Frye SV, Graham DK, Verneris MR, Lee-Sherick AB (2023) Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment. Front Immunol 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1146721","DOI":"10.3389\/fimmu.2023.1146721"},{"key":"6117_CR32","doi-asserted-by":"publisher","unstructured":"Xu ZJ, Gu Y, Wang CZ, Jin Y, Wen XM, Ma JC, Tang LJ, Mao ZW, Qian J, Lin J (2020) The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia. Oncoimmunology 9(1). https:\/\/doi.org\/10.1080\/2162402X.2019.1683347","DOI":"10.1080\/2162402X.2019.1683347"},{"issue":"9","key":"6117_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8(9):726\u2013736. https:\/\/doi.org\/10.1038\/nri2395","journal-title":"Nat Rev Immunol"},{"key":"6117_CR34","doi-asserted-by":"publisher","unstructured":"Pan CY, Hu TZ, Liu P, Ma D, Cao SY, Shang Q, Zhang LX, Chen QZ, Fang Q, Wang JS (2023) BM-MSCs display altered gene expression profiles in B-cell acute lymphoblastic leukemia niches and exert pro-proliferative effects via overexpression of IFI6. J Transl Med 21(1). https:\/\/doi.org\/10.1186\/s12967-023-04464-1","DOI":"10.1186\/s12967-023-04464-1"},{"issue":"6","key":"6117_CR35","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1158\/0008-5472.CAN-18-0921","volume":"79","author":"BZ Carter","year":"2019","unstructured":"Carter BZ, Mak PY, Wang XM, Tao WJ, Ruvolo V, Mak D, Mu H, Burks JK, Andreeff M (2019) An ARC-Regulated IL1\u03b2\/Cox-2\/PGE2\/\u03b2-Catenin\/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML. Cancer Res 79(6):1165\u20131177. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0921","journal-title":"Cancer Res"},{"key":"6117_CR36","doi-asserted-by":"publisher","unstructured":"Cao H, Xiao J, Reeves ME, Payne K, Chen CS, Baylink DJ, Marcucci G, Xu Y (2020) Discovery of proangiogenic CD44\u2009+\u2009mesenchymal cancer stem cells in an acute myeloid leukemia patient\u2019s bone marrow. J Hematol Oncol 13(1). https:\/\/doi.org\/10.1186\/s13045-020-00899-x","DOI":"10.1186\/s13045-020-00899-x"},{"issue":"2","key":"6117_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.leukres.2014.12.001","volume":"39","author":"J Vasold","year":"2015","unstructured":"Vasold J, Wagner M, Drolle H, Deniffel C, K\u00fctt A, Oostendorp R, Sironi S, Rieger C, Fiegl M (2015) The bone marrow microenvironment is a critical player in the NK cell response against acute myeloid leukaemia in vitro. Leuk Res 39(2):257\u2013262. https:\/\/doi.org\/10.1016\/j.leukres.2014.12.001","journal-title":"Leuk Res"},{"issue":"3","key":"6117_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/bjh.15548","volume":"183","author":"LM Wu","year":"2018","unstructured":"Wu LM, Amarachintha S, Xu J, Oley F, Du W (2018) Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity. Br J Haematol 183(3):445\u2013456. https:\/\/doi.org\/10.1111\/bjh.15548","journal-title":"Br J Haematol"},{"issue":"11","key":"6117_CR39","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41375-020-0843-8","volume":"34","author":"LM Wu","year":"2020","unstructured":"Wu LM, Lin QQ, Ma ZL, Chowdhury FA, Mazumder M, Du W (2020) Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs. Leukemia 34(11):3028\u20133041. https:\/\/doi.org\/10.1038\/s41375-020-0843-8","journal-title":"Leukemia"},{"issue":"14","key":"6117_CR40","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-21-3594","volume":"28","author":"G Corradi","year":"2022","unstructured":"Corradi G, Bassani B, Simonetti G, Sangaletti S, Vadakekolathu J, Fontana MC, Pazzaglia M, Gulino A, Tripodo C, Cristiano G et al (2022) Release of IFNgamma by Acute myeloid leukemia cells remodels bone marrow Immune Microenvironment by Inducing Regulatory T Cells. Clin cancer Research: Official J Am Association Cancer Res 28(14):3141\u20133155. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3594","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"6","key":"6117_CR41","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.stemcr.2017.04.019","volume":"8","author":"RD de la Guardia","year":"2017","unstructured":"de la Guardia RD, Lopez-Millan B, Lavoie JR, Bueno C, Casta\u00f1o J, G\u00f3mez-Casares M, Vives S, Palomo L, Juan M, Delgado J et al (2017) Detailed characterization of mesenchymal Stem\/Stromal cells from a large cohort of AML patients demonstrates a definitive link to treatment outcomes. Stem Cell Rep 8(6):1573\u20131586. https:\/\/doi.org\/10.1016\/j.stemcr.2017.04.019","journal-title":"Stem Cell Rep"},{"issue":"9","key":"6117_CR42","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/s41375-020-0775-3","volume":"34","author":"CX Xia","year":"2020","unstructured":"Xia CX, Wang TJ, Cheng H, Dong Y, Weng QT, Sun GH, Zhou PQ, Wang KT, Liu XF, Geng Y et al (2020) Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment. Leukemia 34(9):2375\u20132383. https:\/\/doi.org\/10.1038\/s41375-020-0775-3","journal-title":"Leukemia"},{"key":"6117_CR43","doi-asserted-by":"publisher","unstructured":"Fan R, De Beule N, Maes A, De Bruyne E, Menu E, Vanderkerken K, Maes K, Breckpot K, De Veirman K (2022) The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.1016059","DOI":"10.3389\/fimmu.2022.1016059"},{"key":"6117_CR44","doi-asserted-by":"publisher","unstructured":"Bizymi N, Bjelica S, Kittang AO, Mojsilovic S, Velegraki M, Pontikoglou C, Roussel M, Ersvaer E, Santibanez JF, Lipoldova M et al (2019) Myeloid-derived suppressor cells in Hematologic diseases: promising biomarkers and treatment targets. Hemasphere 3(1). https:\/\/doi.org\/10.1097\/HS9.0000000000000168","DOI":"10.1097\/HS9.0000000000000168"},{"issue":"1","key":"6117_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5(1):3\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0297","journal-title":"Cancer Immunol Res"},{"issue":"21","key":"6117_CR46","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1111\/jcmm.17576","volume":"26","author":"P Peterlin","year":"2022","unstructured":"Peterlin P, Debord C, Eveillard M, Garnier A, Le Bourgeois A, Guillaume T, Jullien M, Bene MC, Chevallier P (2022) Peripheral levels of monocytic myeloid-derived suppressive cells before and after first induction predict relapse and survivals in AML patients. J Cell Mol Med 26(21):5486\u20135492. https:\/\/doi.org\/10.1111\/jcmm.17576","journal-title":"J Cell Mol Med"},{"issue":"3","key":"6117_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/bjc.2016.412","volume":"116","author":"D Anastasiou","year":"2017","unstructured":"Anastasiou D (2017) Tumour microenvironment factors shaping the cancer metabolism landscape. Br J Cancer 116(3):277\u2013286. https:\/\/doi.org\/10.1038\/bjc.2016.412","journal-title":"Br J Cancer"},{"key":"6117_CR48","doi-asserted-by":"publisher","unstructured":"Xu BY, Hu R, Liang Z, Chen T, Chen JY, Hu YX, Jiang YR, Li YH (2021) Metabolic regulation of the bone marrow microenvironment in leukemia. Blood Rev 48. https:\/\/doi.org\/10.1016\/j.blre.2020.100786","DOI":"10.1016\/j.blre.2020.100786"},{"key":"6117_CR49","doi-asserted-by":"publisher","unstructured":"Long YR, Shi HH, He YD, Qi XR (2024) Analyzing the impact of metabolism on immune cells in tumor microenvironment to promote the development of immunotherapy. Front Immunol 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1307228","DOI":"10.3389\/fimmu.2023.1307228"},{"key":"6117_CR50","doi-asserted-by":"publisher","unstructured":"Unterlass JE, Curtin NJ (2019) Warburg and Krebs and related effects in cancer. Expert Rev Mol Med 21. https:\/\/doi.org\/10.1017\/erm.2019.4","DOI":"10.1017\/erm.2019.4"},{"issue":"1","key":"6117_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1189\/jlb.0710417","volume":"89","author":"PM Herst","year":"2011","unstructured":"Herst PM, Howman RA, Neeson PJ, Berridge MV, Ritchie DS (2011) The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. J Leukoc Biol 89(1):51\u201355. https:\/\/doi.org\/10.1189\/jlb.0710417","journal-title":"J Leukoc Biol"},{"issue":"10","key":"6117_CR52","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","volume":"124","author":"WL Chen","year":"2014","unstructured":"Chen WL, Wang JH, Zhao AH, Xu X, Wang YH, Chen TL, Li JM, Mi JQ, Zhu YM, Liu YF et al (2014) A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood 124(10):1645\u20131654. https:\/\/doi.org\/10.1182\/blood-2014-02-554204","journal-title":"Blood"},{"key":"6117_CR53","doi-asserted-by":"publisher","unstructured":"Zambrano A, Molt M, Uribe E, Salas M (2019) Glut 1 in Cancer cells and the Inhibitory Action of Resveratrol as a potential therapeutic strategy. Int J Mol Sci 20(13). https:\/\/doi.org\/10.3390\/ijms20133374","DOI":"10.3390\/ijms20133374"},{"issue":"6","key":"6117_CR54","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/CCO.0b013e328356da72","volume":"24","author":"K Adekola","year":"2012","unstructured":"Adekola K, Rosen ST, Shanmugam M (2012) Glucose transporters in cancer metabolism. Curr Opin Oncol 24(6):650\u2013654. https:\/\/doi.org\/10.1097\/CCO.0b013e328356da72","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"6117_CR55","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41375-023-01912-1","volume":"37","author":"SQ Deng","year":"2023","unstructured":"Deng SQ, Du J, Gale RP, Wang L, Zhan HE, Liu FS, Huang KX, Xu H, Zeng H (2023) Glucose partitioning in the bone marrow micro-environment in acute myeloid leukaemia. Leukemia 37(7):1407\u20131412. https:\/\/doi.org\/10.1038\/s41375-023-01912-1","journal-title":"Leukemia"},{"issue":"5","key":"6117_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ccell.2016.09.006","volume":"30","author":"WL Chen","year":"2016","unstructured":"Chen WL, Wang YY, Zhao AH, Xia L, Xie GX, Su MM, Zhao LJ, Liu JJ, Qu C, Wei RM et al (2016) Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of Acute myeloid leukemia with therapeutic potential. Cancer Cell 30(5):779\u2013791. https:\/\/doi.org\/10.1016\/j.ccell.2016.09.006","journal-title":"Cancer Cell"},{"key":"6117_CR57","doi-asserted-by":"publisher","unstructured":"Yin ZP, Bai L, Li W, Zeng TL, Tian HM, Cui J (2019) Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy. J Exp Clin Cancer Res 38(1). https:\/\/doi.org\/10.1186\/s13046-019-1409-3","DOI":"10.1186\/s13046-019-1409-3"},{"key":"6117_CR58","doi-asserted-by":"publisher","unstructured":"Terr\u00e9n I, Orrantia A, Vitall\u00e9 J, Zenarruzabeitia O, Borrego F (2019) NK Cell Metabolism and Tumor Microenvironment. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.02278","DOI":"10.3389\/fimmu.2019.02278"},{"issue":"1","key":"6117_CR59","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bbcan.2017.04.002","volume":"1868","author":"S Ganapathy-Kanniappan","year":"2017","unstructured":"Ganapathy-Kanniappan S (2017) Linking tumor glycolysis and immune evasion in cancer: emerging concepts and therapeutic opportunities. Biochim Biophys Acta Rev Cancer 1868(1):212\u2013220. https:\/\/doi.org\/10.1016\/j.bbcan.2017.04.002","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"6117_CR60","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41423-021-00753-1","volume":"19","author":"SH Moller","year":"2022","unstructured":"Moller SH, Wang LM, Ho PC (2022) Metabolic programming in dendritic cells tailors immune responses and homeostasis. Cell Mol Immunol 19(3):370\u2013383. https:\/\/doi.org\/10.1038\/s41423-021-00753-1","journal-title":"Cell Mol Immunol"},{"issue":"7519","key":"6117_CR61","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM et al (2014) Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513(7519):559. https:\/\/doi.org\/10.1038\/nature13490","journal-title":"Nature"},{"key":"6117_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cytogfr.2017.05.002","volume":"35","author":"A Sica","year":"2017","unstructured":"Sica A, Straus L, Consonni FM, Travelli C, Genazzani A, Porta C (2017) Metabolic regulation of suppressive myeloid cells in cancer. Cytokine Growth Factor Rev 35:27\u201335. https:\/\/doi.org\/10.1016\/j.cytogfr.2017.05.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"6117_CR63","doi-asserted-by":"publisher","unstructured":"Zhang YN, Huang YT, Hong Y, Lin ZJ, Zha J, Zhu YW, Li ZF, Wang CY, Fang ZH, Zhou ZW et al (2024) Lactate acid promotes PD-1\u2009+\u2009Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia. Int Immunopharmacol 130. https:\/\/doi.org\/10.1016\/j.intimp.2024.111765","DOI":"10.1016\/j.intimp.2024.111765"},{"key":"6117_CR64","doi-asserted-by":"publisher","unstructured":"Huang ZW, Zhang XN, Zhang L, Liu LL, Zhang JW, Sun YX, Xu JQ, Liu QT, Long ZJ (2023) STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct Target Ther 8(1). https:\/\/doi.org\/10.1038\/s41392-023-01605-2","DOI":"10.1038\/s41392-023-01605-2"},{"issue":"13","key":"6117_CR65","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood.2019001034","volume":"134","author":"Y Tabe","year":"2019","unstructured":"Tabe Y, Lorenzi PL, Konopleva M (2019) Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood 134(13):1014\u20131023. https:\/\/doi.org\/10.1182\/blood.2019001034","journal-title":"Blood"},{"issue":"1","key":"6117_CR66","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-023-01569-3","volume":"8","author":"Z Ling","year":"2023","unstructured":"Ling Z, Jiang Y, Ru J, Lu J, Ding B, Wu J (2023) Amino acid metabolism in health and disease. Signal Transduct Target Ther 8(1):345. https:\/\/doi.org\/10.1038\/s41392-023-01569-3","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"6117_CR67","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2014-09-600643","volume":"125","author":"F Mussai","year":"2015","unstructured":"Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, Pong UK, Lo A et al (2015) Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood 125(15):2386\u20132396. https:\/\/doi.org\/10.1182\/blood-2014-09-600643","journal-title":"Blood"},{"issue":"4","key":"6117_CR68","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.2021013201","volume":"139","author":"ML Amaya","year":"2022","unstructured":"Amaya ML, Inguva A, Pei SS, Jones C, Krug A, Ye HB, Minhajuddin M, Winters A, Furtek SL, Gamboni F et al (2022) The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood 139(4):584\u2013596. https:\/\/doi.org\/10.1182\/blood.2021013201","journal-title":"Blood"},{"issue":"8","key":"6117_CR69","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s11864-023-01104-0","volume":"24","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Hu BB, Guo Y, Zhang DY, Zhao YM, Chen Y, Li N, Yu LT (2023) Targeting glutamine metabolism as an attractive therapeutic strategy for Acute myeloid leukemia. Curr Treat Options Oncol 24(8):1021\u20131035. https:\/\/doi.org\/10.1007\/s11864-023-01104-0","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"6117_CR70","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.4049\/jimmunol.0903586","volume":"185","author":"EL Carr","year":"2010","unstructured":"Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, Turay AM, Frauwirth KA (2010) Glutamine uptake and metabolism are Coordinately regulated by ERK\/MAPK during T lymphocyte activation. J Immunol 185(2):1037\u20131044. https:\/\/doi.org\/10.4049\/jimmunol.0903586","journal-title":"J Immunol"},{"issue":"7","key":"6117_CR71","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.cell.2018.10.001","volume":"175","author":"MO Johnson","year":"2018","unstructured":"Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ et al (2018) Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell 175(7):1780. https:\/\/doi.org\/10.1016\/j.cell.2018.10.001","journal-title":"Cell"},{"key":"6117_CR72","doi-asserted-by":"publisher","unstructured":"Klysz D, Tai XG, Robert PA, Craveiro M, Cretenet G, Oburoglu L, Mongellaz C, Floess S, Fritz V, Matias MI et al (2015) Glutamine-dependent \u03b1-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal 8(396). https:\/\/doi.org\/10.1126\/scisignal.aab2610","DOI":"10.1126\/scisignal.aab2610"},{"issue":"12","key":"6117_CR73","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1111\/cas.13827","volume":"109","author":"S Nabe","year":"2018","unstructured":"Nabe S, Yamada T, Suzuki J, Toriyama K, Yasuoka T, Kuwahara M, Shiraishi A, Takenaka K, Yasukawa M, Yamashita M (2018) Reinforce the antitumor activity of CD8+ T cells via glutamine restriction. Cancer Sci 109(12):3737\u20133750. https:\/\/doi.org\/10.1111\/cas.13827","journal-title":"Cancer Sci"},{"key":"6117_CR74","doi-asserted-by":"publisher","unstructured":"Wells G, Kennedy PT, Dahal LN (2021) Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review. Front Immunol 12. https:\/\/doi.org\/10.3389\/fimmu.2021.651687","DOI":"10.3389\/fimmu.2021.651687"},{"key":"6117_CR75","doi-asserted-by":"publisher","unstructured":"Kapor S, Santibanez JF (2021) Myeloid-derived suppressor cells and mesenchymal Stem\/Stromal cells in myeloid malignancies. J Clin Med 10(13). https:\/\/doi.org\/10.3390\/jcm10132788","DOI":"10.3390\/jcm10132788"},{"key":"6117_CR76","doi-asserted-by":"publisher","unstructured":"Moon YW, Hajjar J, Hwu P, Naing A (2015) Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 3. https:\/\/doi.org\/10.1186\/s40425-015-0094-9","DOI":"10.1186\/s40425-015-0094-9"},{"key":"6117_CR77","doi-asserted-by":"publisher","unstructured":"Jitschin R, Braun M, B\u00fcttner M, Dettmer-Wilde K, Bricks J, Berger J, Eckart MJ, Krause SW, Oefner PJ, Le Blanc K et al (2014) CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote. TRegs Blood 124(5):750\u2013760. https:\/\/doi.org\/10.1182\/blood-2013-12-546416","DOI":"10.1182\/blood-2013-12-546416"},{"issue":"5","key":"6117_CR78","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI31178","volume":"117","author":"DH Munn","year":"2007","unstructured":"Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117(5):1147\u20131154. https:\/\/doi.org\/10.1172\/JCI31178","journal-title":"J Clin Invest"},{"issue":"7","key":"6117_CR79","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","volume":"109","author":"A Curti","year":"2007","unstructured":"Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini V, Bonanno G, Rutella S, Durelli I et al (2007) Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25\u2013 into CD25+ T regulatory cells. Blood 109(7):2871\u20132877. https:\/\/doi.org\/10.1182\/blood-2006-07-036863","journal-title":"Blood"},{"issue":"3","key":"6117_CR80","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.bbrc.2018.02.097","volume":"504","author":"M Maan","year":"2018","unstructured":"Maan M, Peters JM, Dutta M, Patterson AD (2018) Lipid metabolism and lipophagy in cancer. Biochem Biophys Res Commun 504(3):582\u2013589. https:\/\/doi.org\/10.1016\/j.bbrc.2018.02.097","journal-title":"Biochem Biophys Res Commun"},{"key":"6117_CR81","doi-asserted-by":"publisher","unstructured":"Li D, Liang JM, Yang W, Guo WB, Song WP, Zhang WZ, Wu X, He BX (2022) A distinct lipid metabolism signature of acute myeloid leukemia with prognostic value. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.876981","DOI":"10.3389\/fonc.2022.876981"},{"key":"6117_CR82","doi-asserted-by":"publisher","unstructured":"Li D, Wu X, Cheng C, Liang JM, Liang YF, Li H, Guo XH, Li RC, Zhang WZ, Song WP (2023) A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia. Front Immunol 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1290968","DOI":"10.3389\/fimmu.2023.1290968"},{"issue":"1","key":"6117_CR83","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","volume":"26","author":"RJ Kishton","year":"2017","unstructured":"Kishton RJ, Sukumar M, Restifo NP (2017) Metabolic regulation of T cell longevity and function in Tumor Immunotherapy. Cell Metab 26(1):94\u2013109. https:\/\/doi.org\/10.1016\/j.cmet.2017.06.016","journal-title":"Cell Metab"},{"issue":"1","key":"6117_CR84","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"XZ Ma","year":"2019","unstructured":"Ma XZ, Bi EG, Lu Y, Su P, Huang CJ, Liu LT, Wang Q, Yang MJ, Kalady MF, Qian JF et al (2019) Cholesterol induces CD8+ T cell exhaustion in the Tumor Microenvironment. Cell Metab 30(1):143. https:\/\/doi.org\/10.1016\/j.cmet.2019.04.002","journal-title":"Cell Metab"},{"issue":"7","key":"6117_CR85","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.ccell.2023.04.016","volume":"41","author":"CS Yan","year":"2023","unstructured":"Yan CS, Zheng L, Jiang ST, Yang HC, Guo J, Jiang LY, Li TZ, Zhang HS, Bai YB, Lou Y et al (2023) Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity. Cancer Cell 41(7):1276. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.016","journal-title":"Cancer Cell"},{"issue":"5","key":"6117_CR86","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","volume":"31","author":"E Ricciotti","year":"2011","unstructured":"Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31(5):986\u20131000. https:\/\/doi.org\/10.1161\/ATVBAHA.110.207449","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6117_CR87","doi-asserted-by":"publisher","unstructured":"Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salome B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C et al (2017) Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun 8. https:\/\/doi.org\/10.1038\/s41467-017-00678-2","DOI":"10.1038\/s41467-017-00678-2"},{"issue":"4","key":"6117_CR88","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"6117_CR89","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y et al (2014) Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280\u20131288. https:\/\/doi.org\/10.1038\/leu.2013.355","journal-title":"Leukemia"},{"key":"6117_CR90","doi-asserted-by":"publisher","unstructured":"Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer JP, Weissman IL, Majeti R (2020) Therapeutic targeting of the Macrophage Immune Checkpoint CD47 in myeloid malignancies. Front Oncol 9. https:\/\/doi.org\/10.3389\/fonc.2019.01380","DOI":"10.3389\/fonc.2019.01380"},{"key":"6117_CR91","doi-asserted-by":"publisher","unstructured":"Dong YQ, Han YX, Huang YS, Jiang SF, Huang ZY, Chen RR, Yu ZJ, Yu K, Zhang SH (2020) PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia. Front Immunol 11. https:\/\/doi.org\/10.3389\/fimmu.2020.01710","DOI":"10.3389\/fimmu.2020.01710"},{"key":"6117_CR92","doi-asserted-by":"publisher","unstructured":"Li W, Wang F, Guo RQ, Bian ZL, Song YP (2022) Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol 15(1). https:\/\/doi.org\/10.1186\/s13045-022-01328-x","DOI":"10.1186\/s13045-022-01328-x"},{"key":"6117_CR93","doi-asserted-by":"publisher","unstructured":"Jiang Y, Li Y, Zhu B (2015) T-cell exhaustion in the tumor microenvironment. Cell Death Dis 6. https:\/\/doi.org\/10.1038\/cddis.2015.162","DOI":"10.1038\/cddis.2015.162"},{"issue":"10","key":"6117_CR94","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW et al (2018) Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest 128(10):4654\u20134668. https:\/\/doi.org\/10.1172\/JCI99317","journal-title":"J Clin Invest"},{"issue":"2","key":"6117_CR95","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00262-021-02978-5","volume":"71","author":"G Liu","year":"2022","unstructured":"Liu G, Zhang Q, Yang J, Li X, Xian L, Li W, Lin T, Cheng J, Lin Q, Xu X et al (2022) Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis. Cancer Immunol Immunother 71(2):277\u2013287. https:\/\/doi.org\/10.1007\/s00262-021-02978-5","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"6117_CR96","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville R, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM et al (2015) Chemotherapy-refractory diffuse large B-Cell lymphoma and indolent B-Cell malignancies can be effectively treated with autologous T cells expressing an Anti-CD19 chimeric Antigen receptor. J Clin Oncol 33(6):531\u2013540. https:\/\/doi.org\/10.1200\/JCO.2014.56.2025","journal-title":"J Clin Oncol"},{"key":"6117_CR97","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.leukres.2017.11.011","volume":"64","author":"A Pando","year":"2018","unstructured":"Pando A, Reagan JL, Quesenberry P, Fast LD (2018) Extracellular vesicles in leukemia. Leuk Res 64:52\u201360. https:\/\/doi.org\/10.1016\/j.leukres.2017.11.011","journal-title":"Leuk Res"},{"key":"6117_CR98","doi-asserted-by":"publisher","unstructured":"Longjohn MN, Hudson JBJ, Smith NC, Rise ML, Moorehead PC, Christian SL (2021) Deciphering the messages carried by extracellular vesicles in hematological malignancies. Blood Rev 46. https:\/\/doi.org\/10.1016\/j.blre.2020.100734","DOI":"10.1016\/j.blre.2020.100734"},{"issue":"6","key":"6117_CR99","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/bloodadvances.2021006195","volume":"6","author":"J Swatler","year":"2022","unstructured":"Swatler J, Turos-Korgul L, Brewinska-Olchowik M, De Biasi S, Dudka W, Bac VL, Kominek A, Cyranowski S, Pilanc P, Mohammadi E et al (2022) 4-1BBL-containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells. Blood Adv 6(6):1879\u20131894. https:\/\/doi.org\/10.1182\/bloodadvances.2021006195","journal-title":"Blood Adv"},{"key":"6117_CR100","doi-asserted-by":"publisher","unstructured":"Otmani K, Rouas R, Lagneaux L, Krayem M, Duvillier H, Berehab M, Lewalle P (2023) Acute myeloid leukemia-derived exosomes deliver mir-24-3p to hinder the T-cell immune response through DENN\/MADD targeting in the NF-\u03baB signaling pathways. Cell Commun Signal 21(1). https:\/\/doi.org\/10.1186\/s12964-023-01259-1","DOI":"10.1186\/s12964-023-01259-1"},{"key":"6117_CR101","doi-asserted-by":"publisher","unstructured":"Agha DM, Rouas R, Najar M, Bouhtit F, Fayyad-Kazan H, Lagneaux L, Bron D, Meuleman N, Lewalle P, Merimi M (2020) Impact of bone marrow miR-21 expression on Acute myeloid leukemia T lymphocyte fragility and dysfunction. Cells 9(9). https:\/\/doi.org\/10.3390\/cells9092053","DOI":"10.3390\/cells9092053"},{"issue":"17","key":"6117_CR102","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-20-0024","volume":"80","author":"S Tohumeken","year":"2020","unstructured":"Tohumeken S, Baur R, Boettcher M, Stoll A, Loschinski R, Panagiotidis K, Braun M, Saul D, Voelkl S, Baur AS et al (2020) Palmitoylated proteins on AML-Derived Extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2\/Akt\/mTOR. Signal Cancer Res 80(17):3663\u20133676. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0024","journal-title":"Signal Cancer Res"},{"key":"6117_CR103","doi-asserted-by":"publisher","unstructured":"Du A, Yang Q, Sun X, Zhao Q (2023) Exosomal circRNA-001264 promotes AML immunosuppression through induction of M2-like macrophages and PD-L1 overexpression. Int Immunopharmacol 124. https:\/\/doi.org\/10.1016\/j.intimp.2023.110868","DOI":"10.1016\/j.intimp.2023.110868"},{"key":"6117_CR104","doi-asserted-by":"publisher","unstructured":"Han Y, Dong Y, Yang Q, Xu W, Jiang S, Yu Z, Yu K, Zhang S (2018) Acute myeloid leukemia cells express ICOS Ligand to Promote the Expansion of Regulatory T Cells. Front Immunol 9. https:\/\/doi.org\/10.3389\/fimmu.2018.02227","DOI":"10.3389\/fimmu.2018.02227"},{"key":"6117_CR105","doi-asserted-by":"publisher","unstructured":"Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E, Pegoraro A, Portararo P, Jandus C, Bontadini A et al (2017) ATP release from chemotherapy-treated dying leukemia cells elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and tolerogenic dendritic cells. Front Immunol 8. https:\/\/doi.org\/10.3389\/fimmu.2017.01918","DOI":"10.3389\/fimmu.2017.01918"},{"issue":"18","key":"6117_CR106","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1182\/blood-2009-03-208181","volume":"114","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, Levine BL, Riddle M, June CH, Vallera DA et al (2009) Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 114(18):3793\u20133802. https:\/\/doi.org\/10.1182\/blood-2009-03-208181","journal-title":"Blood"},{"issue":"25","key":"6117_CR107","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","volume":"123","author":"V Bachanova","year":"2014","unstructured":"Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K et al (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123(25):3855\u20133863. https:\/\/doi.org\/10.1182\/blood-2013-10-532531","journal-title":"Blood"},{"key":"6117_CR108","doi-asserted-by":"publisher","unstructured":"Pousse L, Korfi K, Medeiros BCC, Berrera M, Kumpesa N, Eckmann J, Hutter IK, Griesser V, Karanikas V, Klein C et al (2023) CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25\u2009+\u2009blasts in acute myeloid leukemia. Front Oncol 13. https:\/\/doi.org\/10.3389\/fonc.2023.1150149","DOI":"10.3389\/fonc.2023.1150149"},{"issue":"44","key":"6117_CR109","doi-asserted-by":"publisher","first-page":"17945","DOI":"10.1073\/pnas.1316796110","volume":"110","author":"D Sugiyama","year":"2013","unstructured":"Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y et al (2013) Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 110(44):17945\u201317950. https:\/\/doi.org\/10.1073\/pnas.1316796110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"6117_CR110","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1182\/bloodadvances.2022008327","volume":"7","author":"K Watanabe","year":"2023","unstructured":"Watanabe K, Gomez AM, Kuramitsu S, Siurala M, Da T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD Jr et al (2023) Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. Blood Adv 7(14):3416\u20133430. https:\/\/doi.org\/10.1182\/bloodadvances.2022008327","journal-title":"Blood Adv"},{"key":"6117_CR111","doi-asserted-by":"publisher","unstructured":"Bai H, Peng Y, Li Y, Duan J, Fu W, Liang X, Yu W, Zhang Q (2022) Cytarabine-induced TNF\u03b1 promotes the expansion and suppressive functions of myeloid-derived suppressor cells in acute myeloid leukaemia. Scand J Immunol 95(6). https:\/\/doi.org\/10.1111\/sji.13158","DOI":"10.1111\/sji.13158"},{"issue":"10","key":"6117_CR112","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2017.21","volume":"31","author":"EA Eksioglu","year":"2017","unstructured":"Eksioglu EA, Chen X, Heider K, Rueter B, McGraw KL, Basiorka AA, Wei M, Burnette A, Cheng P, Lancet J et al (2017) Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia 31(10):2172\u20132180. https:\/\/doi.org\/10.1038\/leu.2017.21","journal-title":"Leukemia"},{"issue":"6","key":"6117_CR113","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","volume":"30","author":"P Cheng","year":"2022","unstructured":"Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA et al (2022) Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther 30(6):2315\u20132326. https:\/\/doi.org\/10.1016\/j.ymthe.2022.02.005","journal-title":"Mol Ther"},{"key":"6117_CR114","doi-asserted-by":"publisher","unstructured":"Jitschin R, Saul D, Braun M, Tohumeken S, Voelkl S, Kischel R, Lutteropp M, Dos Santos C, Mackensen A, Mougiakakos D (2018) CD33\/CD3-bispecific T-cell engaging (BiTE\u00ae) antibody construct targets monocytic AML myeloid-derived suppressor cells. J Immunother Cancer 6. https:\/\/doi.org\/10.1186\/s40425-018-0432-9","DOI":"10.1186\/s40425-018-0432-9"},{"key":"6117_CR115","doi-asserted-by":"publisher","unstructured":"Liu JT, Wei YH, Jia WB, Can C, Wang RQ, Yang XY, Gu CY, Liu FB, Ji CY, Ma DX (2022) Chenodeoxycholic acid suppresses AML progression through promoting lipid peroxidation via ROS\/p38 MAPK\/DGAT1 pathway and inhibiting M2 macrophage polarization. Redox Biol 56. https:\/\/doi.org\/10.1016\/j.redox.2022.102452","DOI":"10.1016\/j.redox.2022.102452"},{"key":"6117_CR116","doi-asserted-by":"publisher","unstructured":"Yang X, Feng WL, Wang R, Yang FF, Wang LN, Chen SY, Ru YX, Cheng T, Zheng GG (2018) Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects. Oncoimmunology 7(4). https:\/\/doi.org\/10.1080\/2162402X.2017.1412910","DOI":"10.1080\/2162402X.2017.1412910"},{"issue":"4","key":"6117_CR117","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3324\/haematol.2020.270421","volume":"107","author":"P Pe\u00f1a-Mart\u00ednez","year":"2022","unstructured":"Pe\u00f1a-Mart\u00ednez P, Ramakrishnan R, H\u00f6gberg C, Jansson C, Nord DG, J\u00e4r\u00e5s M (2022) Interleukin 4 promotes phagocytosis of murine leukemia cells counteracted by CD47 upregulation. Haematologica 107(4):816\u2013824. https:\/\/doi.org\/10.3324\/haematol.2020.270421","journal-title":"Haematologica"},{"issue":"23","key":"6117_CR118","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.2023019782","volume":"142","author":"CH Man","year":"2023","unstructured":"Man CH, Lam W, Dang CC, Zeng XY, Zheng LC, Chan N, Ng KL, Chan KC, Kwok TH, Ng T et al (2023) Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML. Blood 142(23):2002\u20132015. https:\/\/doi.org\/10.1182\/blood.2023019782","journal-title":"Blood"},{"key":"6117_CR119","doi-asserted-by":"publisher","unstructured":"Tilekar K, Upadhyay N, Schweipert M, Hess JD, Macias LH, Mrowka P, Meyer-Almes FJ, Aguilera RJ, Iancu CV, Choe JY et al (2020) Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells. Eur J Pharm Sci 154. https:\/\/doi.org\/10.1016\/j.ejps.2020.105512","DOI":"10.1016\/j.ejps.2020.105512"},{"issue":"4","key":"6117_CR120","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3324\/haematol.2020.246843","volume":"106","author":"H \u00c5backa","year":"2021","unstructured":"\u00c5backa H, Hansen JS, Huang P, Venskutonyte R, Hyrenius-Wittsten A, Poli G, Tuccinardi T, Granchi C, Minutolo F, Hagstr\u00f6m-Andersson AK et al (2021) Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance. Haematologica 106(4):1163\u20131166. https:\/\/doi.org\/10.3324\/haematol.2020.246843","journal-title":"Haematologica"},{"key":"6117_CR121","doi-asserted-by":"publisher","unstructured":"Grzybowski MM, Stalczak PS, Pomper P, Blaszczyk R, Borek B, Gzik A, Nowicka J, Jedrzejczak K, Brzezinska J, Rejczak T et al (2022) OATD-02 validates the benefits of pharmacological inhibition of Arginase 1 and 2. Cancer Cancers (Basel) 14(16). https:\/\/doi.org\/10.3390\/cancers14163967","DOI":"10.3390\/cancers14163967"},{"issue":"8","key":"6117_CR122","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/ijc.32028","volume":"145","author":"F Mussai","year":"2019","unstructured":"Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, Perry T, Kearns P, Cheng P, Keeshan K et al (2019) Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. Int J Cancer 145(8):2201\u20132208. https:\/\/doi.org\/10.1002\/ijc.32028","journal-title":"Int J Cancer"},{"issue":"1","key":"6117_CR123","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12032-010-9459-6","volume":"28","author":"N El Kholy","year":"2011","unstructured":"El Kholy N, Sallam M, Ahmed M, Sallam R, Asfour I, Hammouda J, Habib H, Abu-Zahra F (2011) Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells. Med Oncol 28(1):270\u2013278. https:\/\/doi.org\/10.1007\/s12032-010-9459-6","journal-title":"Med Oncol"},{"issue":"9","key":"6117_CR124","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.3390\/molecules180910132","volume":"18","author":"MG Iachininoto","year":"2013","unstructured":"Iachininoto MG, Nuzzolo ER, Bonanno G, Mariotti A, Procoli A, Locatelli F, De Cristofaro R, Rutella S (2013) Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-Dioxygenase 1 (IDO1) activity in Acute myeloid leukaemia cells. Molecules 18(9):10132\u201310145. https:\/\/doi.org\/10.3390\/molecules180910132","journal-title":"Molecules"},{"key":"6117_CR125","doi-asserted-by":"publisher","unstructured":"Emadi A, Duong VH, Pantin J, Imran M, Koka R, Singh Z, Sausville EA, Law JY, Lee ST, Shi HD et al (2018) Indoximod combined with Standard Induction Chemotherapy Is Well Tolerated and induces a high rate of complete remission with MRD-Negativity in patients with newly diagnosed AML: results from a phase 1 trial. Blood 132. https:\/\/doi.org\/10.1182\/blood-2018-99-117433","DOI":"10.1182\/blood-2018-99-117433"},{"key":"6117_CR126","doi-asserted-by":"publisher","unstructured":"Hammon K, Renner K, Althammer M, Voll F, Babl N, Decking S, Siska PJ, Matos C, Conejo ZEC, Mendes K et al (2024) D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2023.283597","DOI":"10.3324\/haematol.2023.283597"},{"key":"6117_CR127","doi-asserted-by":"publisher","unstructured":"Galluzzi L, Kroemer G (2018) Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate. Oncoimmunology 7(12). https:\/\/doi.org\/10.1080\/2162402X.2018.1528815","DOI":"10.1080\/2162402X.2018.1528815"},{"issue":"10","key":"6117_CR128","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1182\/blood.2019004500","volume":"136","author":"L Fultang","year":"2020","unstructured":"Fultang L, Booth S, Yogev O, Da Costa BM, Tubb V, Panetti S, Stavrou V, Scarpa U, Jankevics A, Lloyd G et al (2020) Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood 136(10):1155\u20131160. https:\/\/doi.org\/10.1182\/blood.2019004500","journal-title":"Blood"},{"issue":"7888","key":"6117_CR129","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41586-021-04109-7","volume":"600","author":"L Long","year":"2021","unstructured":"Long L, Wei J, Lim SA, Raynor JL, Shi H, Connelly JP, Wang H, Guy C, Xie B, Chapman NM et al (2021) CRISPR screens unveil signal hubs for nutrient licensing of T cell immunity. Nature 600(7888):308. https:\/\/doi.org\/10.1038\/s41586-021-04109-7","journal-title":"Nature"},{"issue":"7787","key":"6117_CR130","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei J, Long L, Zheng W, Dhungana Y, Lim SA, Guy C, Wang Y, Wang Y, Qian C, Xu B et al (2019) Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature 576(7787):471. https:\/\/doi.org\/10.1038\/s41586-019-1821-z","journal-title":"Nature"},{"issue":"6382","key":"6117_CR131","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"issue":"2","key":"6117_CR132","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P et al (2016) Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 375(2):143\u2013153. https:\/\/doi.org\/10.1056\/NEJMoa1601202","journal-title":"N Engl J Med"},{"issue":"24","key":"6117_CR133","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood.2019004710","volume":"135","author":"MS Davids","year":"2020","unstructured":"Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP et al (2020) A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood 135(24):2182\u20132191. https:\/\/doi.org\/10.1182\/blood.2019004710","journal-title":"Blood"},{"key":"6117_CR134","doi-asserted-by":"publisher","unstructured":"Liu XQ, Zhang YF, Li KM, Liu YH, Xu JQ, Ma JJ, An LC, Wang H, Chu XX (2021) A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma. Transl Oncol 14(7). https:\/\/doi.org\/10.1016\/j.tranon.2021.101085","DOI":"10.1016\/j.tranon.2021.101085"},{"issue":"2","key":"6117_CR135","first-page":"615","volume":"12","author":"YJ Ma","year":"2022","unstructured":"Ma YJ, Dai HP, Cui QY, Cui W, Zhu WJ, Qu CJ, Kang LQ, Zhu MQ, Zhu XM, Liu DD et al (2022) Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. Am J Cancer Res 12(2):615","journal-title":"Am J Cancer Res"},{"key":"6117_CR136","doi-asserted-by":"publisher","unstructured":"Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, Gohil M, Chen LH, Hong S, Ravikumar P et al (2023) Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity 56(10). https:\/\/doi.org\/10.1016\/j.immuni.2023.09.001","DOI":"10.1016\/j.immuni.2023.09.001"},{"key":"6117_CR137","doi-asserted-by":"publisher","unstructured":"Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X, He X, Lu W, Zhao M (2020) Targeting Bcl-2 proteins in Acute myeloid leukemia. Front Oncol 10. https:\/\/doi.org\/10.3389\/fonc.2020.584974","DOI":"10.3389\/fonc.2020.584974"},{"issue":"1","key":"6117_CR138","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s43018-020-00165-6","volume":"2","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Konopleva MY (2021) A venetoclax bench-to-bedside story. Nat Cancer 2(1):3\u20135. https:\/\/doi.org\/10.1038\/s43018-020-00165-6","journal-title":"Nat Cancer"},{"key":"6117_CR139","doi-asserted-by":"publisher","unstructured":"Zhigarev D, Varshavsky A, MacFarlane AW, Jayaguru P, Barreyro L, Khoreva M, Dulaimi E, Nejati R, Drenberg C, Campbell KS (2022) Lymphocyte exhaustion in AML patients and impacts of HMA\/Venetoclax or intensive chemotherapy on their Biology. Cancers (Basel) 14(14). https:\/\/doi.org\/10.3390\/cancers14143352","DOI":"10.3390\/cancers14143352"},{"issue":"12","key":"6117_CR140","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1182\/bloodadvances.2022008221","volume":"7","author":"CE Teh","year":"2023","unstructured":"Teh CE, Peng H, Luo M, Tan T, Trussart M, Howson LJ, Chua CC, Muttiah C, Brown F, Ritchie ME et al (2023) Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells. Blood Adv 7(12):2733\u20132745. https:\/\/doi.org\/10.1182\/bloodadvances.2022008221","journal-title":"Blood Adv"},{"issue":"3","key":"6117_CR141","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, Mirali S, Wang X, Gronda M, Jitkova Y et al (2021) Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood 138(3):234\u2013245. https:\/\/doi.org\/10.1182\/blood.2020009081","journal-title":"Blood"},{"key":"6117_CR142","doi-asserted-by":"publisher","unstructured":"Wu H, Li K, Pan W, Guo M, Qiu D, He Y, Li Y, Huang Y (2022) Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D\/NKG2DL activation pathway. Int Immunopharmacol 104. https:\/\/doi.org\/10.1016\/j.intimp.2021.108497","DOI":"10.1016\/j.intimp.2021.108497"},{"key":"6117_CR143","doi-asserted-by":"publisher","unstructured":"Ren J, Tao Y, Peng M, Xiao Q, Jing Y, Huang J, Yang J, Lin C, Sun M, Lei L et al (2022) Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8\u2009+\u2009T cell immune function in acute myeloid leukemia. Cell Death Dis 13(10). https:\/\/doi.org\/10.1038\/s41419-022-05357-9","DOI":"10.1038\/s41419-022-05357-9"},{"issue":"19","key":"6117_CR144","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1182\/bloodadvances.2020002810","volume":"4","author":"JE Davis","year":"2020","unstructured":"Davis JE, Handunnetti SM, Ludford-Menting M, Sharpe C, Blombery P, Anderson MA, Roberts AW, Seymour JF, Tam CS, Ritchie DS et al (2020) Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Adv 4(19):4849\u20134859. https:\/\/doi.org\/10.1182\/bloodadvances.2020002810","journal-title":"Blood Adv"},{"issue":"17","key":"6117_CR145","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","volume":"3","author":"I de Weerdt","year":"2019","unstructured":"de Weerdt I, Hofland T, de Boer R, Dobber JA, Dubois J, van Nieuwenhuize D, Mobasher M, de Boer F, Hoogendoorn M, Velders GA et al (2019) Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv 3(17):2642\u20132652. https:\/\/doi.org\/10.1182\/bloodadvances.2019000360","journal-title":"Blood Adv"},{"key":"6117_CR146","doi-asserted-by":"publisher","unstructured":"Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N et al (2022) Modulation of BCL-2 in both T Cells and Tumor Cells to enhance chimeric Antigen receptor T-cell immunotherapy against Cancer. Cancer Discov 12(10). https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1026","DOI":"10.1158\/2159-8290.CD-21-1026"},{"issue":"2","key":"6117_CR147","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/leu.2012.195","volume":"27","author":"AYH Leung","year":"2013","unstructured":"Leung AYH, Man C, Kwong Y (2013) FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia 27(2):260\u2013268. https:\/\/doi.org\/10.1038\/leu.2012.195","journal-title":"Leukemia"},{"issue":"4","key":"6117_CR148","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","volume":"25","author":"R Bystrom","year":"2023","unstructured":"Bystrom R, Levis MJ (2023) An update on FLT3 in Acute myeloid leukemia: Pathophysiology and Therapeutic Landscape. Curr Oncol Rep 25(4):369\u2013378. https:\/\/doi.org\/10.1007\/s11912-023-01389-2","journal-title":"Curr Oncol Rep"},{"key":"6117_CR149","doi-asserted-by":"publisher","unstructured":"Wu M, Li C, Zhu X (2018) FLT3 inhibitors in acute myeloid leukemia. J Hematol Oncol 11. https:\/\/doi.org\/10.1186\/s13045-018-0675-4","DOI":"10.1186\/s13045-018-0675-4"},{"issue":"5","key":"6117_CR150","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41409-022-01619-4","volume":"57","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Hasegawa Y, Hashimoto D, Senjo H, Kikuchi R, Chen X, Yoneda K, Sekiguchi T, Kawase T, Tsuzuki H et al (2022) Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 57(5):775\u2013780. https:\/\/doi.org\/10.1038\/s41409-022-01619-4","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"6117_CR151","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew NR, Baumgartner F, Braun L, O\u2019Sullivan D, Thomas S, Waterhouse M, Mueller TA, Hanke K, Taromi S, Apostolova P et al (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24(3):282. https:\/\/doi.org\/10.1038\/nm.4484","journal-title":"Nat Med"},{"key":"6117_CR152","doi-asserted-by":"publisher","unstructured":"Kaito Y, Hirano M, Futami M, Nojima M, Tamura H, Tojo A, Imai Y (2022) CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia. Oncol Lett 23(2). https:\/\/doi.org\/10.3892\/ol.2021.13169","DOI":"10.3892\/ol.2021.13169"},{"key":"6117_CR153","doi-asserted-by":"publisher","unstructured":"Gutierrez L, Jang M, Zhang T, Akhtari M, Alachkar H (2018) Midostaurin reduces Regulatory T cells markers in Acute myeloid leukemia. Sci Rep 8. https:\/\/doi.org\/10.1038\/s41598-018-35978-0","DOI":"10.1038\/s41598-018-35978-0"},{"issue":"5","key":"6117_CR154","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","volume":"32","author":"H Jetani","year":"2018","unstructured":"Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Briones Meijide J, Bonig H, Herr W, Sierra J, Einsele H et al (2018) CAR T-cells targeting FLT3 have potent activity against FLT3\u2013ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 32(5):1168\u20131179. https:\/\/doi.org\/10.1038\/s41375-018-0009-0","journal-title":"Leukemia"},{"key":"6117_CR155","doi-asserted-by":"publisher","unstructured":"Li K, Wu H, Pan W, Guo M, Qiu D, He Y, Li Y, Yang D, Huang Y (2022) A novel approach for relapsed\/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CART cells and gilteritinib. Mol Cancer 21(1). https:\/\/doi.org\/10.1186\/s12943-022-01541-9","DOI":"10.1186\/s12943-022-01541-9"},{"issue":"2","key":"6117_CR156","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/leu.2017.257","volume":"32","author":"K Reiter","year":"2018","unstructured":"Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, Metzeler KH, Doerfel D, Salih HR, Jung G et al (2018) Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia 32(2):313\u2013322. https:\/\/doi.org\/10.1038\/leu.2017.257","journal-title":"Leukemia"},{"issue":"5","key":"6117_CR157","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/bjh.15975","volume":"186","author":"F Fasslrinner","year":"2019","unstructured":"Fasslrinner F, Arndt C, Koristka S, Feldmann A, Altmann H, von Bonin M, Schmitz M, Bornhauser M, Bachmann M (2019) Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia. Br J Haematol 186(5):735\u2013740. https:\/\/doi.org\/10.1111\/bjh.15975","journal-title":"Br J Haematol"},{"key":"6117_CR158","doi-asserted-by":"publisher","unstructured":"Fruchtman H, Avigan ZM, Waksal JA, Brennan N, Mascarenhas JO (2024) Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia. Leukemia. https:\/\/doi.org\/10.1038\/s41375-024-02246-2","DOI":"10.1038\/s41375-024-02246-2"},{"issue":"10","key":"6117_CR159","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi CJ, Yan H (2021) The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol 18(10):645\u2013661. https:\/\/doi.org\/10.1038\/s41571-021-00521-0","journal-title":"Nat Rev Clin Oncol"},{"key":"6117_CR160","doi-asserted-by":"publisher","unstructured":"Boettcher M, Renner K, Berger R, Mentz K, Thomas S, Cardenas-Conejo ZE, Dettmer K, Oefner PJ, Mackensen A, Kreutz M et al (2018) D-2-hydroxyglutarate interferes with HIF-1 stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. Oncoimmunology 7(7). https:\/\/doi.org\/10.1080\/2162402X.2018.1445454","DOI":"10.1080\/2162402X.2018.1445454"},{"issue":"8","key":"6117_CR161","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","volume":"24","author":"L Bunse","year":"2018","unstructured":"Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K et al (2018) Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med 24(8):1192. https:\/\/doi.org\/10.1038\/s41591-018-0095-6","journal-title":"Nat Med"},{"issue":"4","key":"6117_CR162","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41375-021-01487-9","volume":"36","author":"KI Sunthankar","year":"2022","unstructured":"Sunthankar KI, Jenkins MT, Cote CH, Patel SB, Welner RS, Ferrell PB (2022) Isocitrate dehydrogenase mutations are associated with altered IL-1 beta responses in acute myeloid leukemia. Leukemia 36(4):923\u2013934. https:\/\/doi.org\/10.1038\/s41375-021-01487-9","journal-title":"Leukemia"},{"issue":"3","key":"6117_CR163","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","volume":"12","author":"M Wu","year":"2022","unstructured":"Wu M, Shi L, Dubrot J, Merritt J, Vijay V, Wei T, Kessler E, Olander KE, Adil R, Pankaj A et al (2022) Mutant IDH inhibits IFN\u03b3-TET2 signaling to promote immunoevasion and tumor maintenance in Cholangiocarcinoma. Cancer Discov 12(3):812\u2013835. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1077","journal-title":"Cancer Discov"},{"key":"6117_CR164","doi-asserted-by":"publisher","unstructured":"Palau A, Segerberg F, Lidschreiber M, Lidschreiber K, Naughton AJ, Needhamsen M, Jung LA, Jagodic M, Cramer P, Lehmann S et al (2023) Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells. Leukemia. https:\/\/doi.org\/10.1038\/s41375-023-01972-3","DOI":"10.1038\/s41375-023-01972-3"},{"issue":"3","key":"6117_CR165","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3626","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11(3):215\u2013233. https:\/\/doi.org\/10.1038\/nrd3626","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"6117_CR166","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of Conventional Chemotherapy and targeted Anticancer agents. Cancer Cell 28(6):690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012","journal-title":"Cancer Cell"},{"key":"6117_CR167","doi-asserted-by":"publisher","unstructured":"Corradi G, Forte D, Cristiano G, Polimeno A, Ciciarello M, Salvestrini V, Bandini L, Robustelli V, Ottaviani E, Cavo M et al (2024) Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells. Front Immunol 15. https:\/\/doi.org\/10.3389\/fimmu.2024.1386517","DOI":"10.3389\/fimmu.2024.1386517"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06117-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:15:10Z","timestamp":1735848910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06117-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":167,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6117"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06117-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}